Table 1.
Baseline characteristics of patients.
| ETV | LAM | P-values | |
|---|---|---|---|
| Number of cases | 135 | 68 | |
| Age (years) | 51.7 ± 11.7 | 45.5 ± 12.1 | <0.001 |
| Gender (male/female) | 83/52 | 49/19 | 0.135 |
| HBeAg (+/-) | 64/71 | 45/23 | 0.011 |
| Genotype (A/B/C/unknown) | 0/11/78/46 | 1/6/57/4 | 0.427 |
| HBV DNA (log IU/mL) (≤5.0/> 5.0/unknown) | 27/108/0 | 3/55/10 | 0.009 |
| ALT (IU/L) | 161 ± 195 | 353 ± 394 | <0.001 |
| Platelets (×104/mm3) | 16.3 ± 5.9 | 16.9 ± 7.0 | 0.556 |
| APRI | 2.49 ± 4.19 | 6.52 ± 6.98 | <0.001 |
| Follow-up period (months) | 26.9 ± 21.6 | 49.0 ± 39.7 | <0.001 |
ETV, entecavir; LAM, lamivudine; HBeAg, hepatitis B e antigen; N.D., not determined; HBV DNA, hepatitis B virus deoxyribonucleic acid; ALT, alanine aminotransferase; APRI, aspartate aminotransferase platelet ratio index. Continuous variables are expressed as mean ± standard deviation.